Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore
The collaboration between both the ministries will play an important role in enhancing the skill and service sector related to Ayurveda
Proposed combination enhances Pfizer’s position as a leading company in oncology
ALPLA is expanding its presence in the global market for pharmaceutical packaging by establishing a joint venture with Inden Pharma
The company will be submitting the responses to US FDA observations within stipulated timeline
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
Subscribe To Our Newsletter & Stay Updated
